[1] U.S. Food and Drug Administration. Approved cellular and gene therapy products from: https://www.fda.gov/vaccines-blood-biologics/cellulargene-therapy products/approved-cellular-and-gene-therapy-products; last accessed 25/01/2025.
[2] European Medicine Agency. Approved cellular and gene therapy products from: https://www.ema.europa.eu/en/human-regulatory/overview/advancedtherapy-medicinal-products-overview; last accessed 25/01/2025.
[3] Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery[J]. Nat Rev Drug Discov,2019,18(5):358-378.
[4] Ho A, Orton R, Tayler R, et al. Adeno-associated virus 2 infection in children with non-A-E hepatitis[J]. Nature,2023,617(7961):555-563.
[5] Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8[J]. Mol Ther,2006,14(1):45-53.
[6] Yan Z, Yan H, Ou H. Human thyroxine binding globulin (TBG) promoter directs efficient and sustaining transgene expression in liver-specific pattern[J]. Gene, 2012,506(2):289-294.
[7] Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues[J]. Blood,2021,138(11): 923-931.
[8] Miesbach W, Klamroth R, Oldenburg J, Tiede A. Gene therapy for hemophilia-opportunities and risks. Dtsch Arztebl Int 2022 [Forthcoming)].
[9] Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B[J]. N Engl J Med,2011,365(25):2357-2365.
[10] Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A[J]. N Engl J Med,2022,386(11):1013-1025.
[11] Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B[J]. N Engl J Med,2023,388(8):706-718.
[12] Li H, Sheng C, Liu H, et al. Inhibition of HBV Expression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9[J]. Front Immunol,2018,9:2080.
[13] Xu Z, Zhao L, Zhong Y, et al. A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA[J]. Cell Mol Gastroenterol Hepatol,2022,13(4):1001-1017.
[14] Chen M, Wang GJ, Diao Y, et al. Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo[J]. World J Gastroenterol,2005,11(26):4045-4051.
[15] Martinez M, Harding CO, Schwank G, et al. State-of-the-art 2023 on gene therapy for phenylketonuria[J]. J Inherit Metab Dis,2024,47(1):80-92.
[16] Malhotra JD, Miao H, Zhang K, et al. Antioxidants reduce endoplasmic reticulum stress and improve protein secretion[J]. Proc Natl Acad Sci USA, 2008,105:18525-18530.
[17] Poothong J, Pottekat A, Siirin M, et al. Factor VIII exhibits chaperonedependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum[J]. Blood,2020,135(21):1899-1911.
[18] Miesbach W, Oldenburg J, Klamroth R, et al. Gene therapy of hemophilia: recommendations from the German, Austrian, and Swiss society for thrombosis and haemostasis research (GTH)[J]. Hamostaseologie,2023,43(3):196-207.
[19] Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity[J]. Sci Transl Med,2014,6(227): 227ra33.
[20] Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1[J]. J Clin Invest,2008,118(9):3132-3142.
[21] Nault JC, Datta S, Imbeaud S, et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas[J]. Nat Genet,2015,47(10):1187-1193.
[22] Kapelanski-Lamoureux A, Chen Z, Gao ZH, et al. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma[J]. Mol Ther,2022,30:3542-3551. |
